Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Anemia Clinical Trial

Official title:

Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Participants With Multiple Myeloma or Myelofibrosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03303950
• Other study ID #: HCI98381
• Status: Terminated
• Phase: Phase 2
• Start date: March 30, 2018
• Est. completion date: February 19, 2020

Study information

• Verified date: May 2022
• Source: University of Utah
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.

Description:

PRIMARY OBJECTIVES:

I. To evaluate non-relapse mortality (NRM) up to day +100.

SECONDARY OBJECTIVES:

I. To evaluate non-relapse mortality (NRM) up to day +365. II. To evaluate the incidence of acute graft versus host disease (GVHD) and chronic GVHD up to day +365 post-transplant.

III. To evaluate the overall survival and disease free survival up to 1 year. IV. To evaluate clinical response and molecular response (complete response and partial response) up to 1 year.

OUTLINE:

Participants receive busulfan intravenously (IV) over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo hematopoietic cell transplantation (HSCT) on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.

After completion of study treatment, participants are followed up for 1 year.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: February 19, 2020
• Est. primary completion date: May 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Participants must have one of the following diagnoses of multiple myeloma (MM) or primary/secondary myelofibrosis (MF)

• Participants must have histologically documented multiple myeloma (MM)

• Participants in early relapse (less than 24 months from initiation of systemic anti-myeloma therapy which may include single or planned tandem autologous transplant) after primary therapy that included and autologous HSCT; OR

• Later stage; OR

• High risk factors defined by the presence of any one of the following detected at any time prior to enrollment: deletion of chromosome 13 by conventional cytogenetics, hypodiploidy, abnormality in chromosome 1 (1q amplification or 1p deletion), t(4;14), t(14;16), t(14;20) or deletion of 17p by fluorescence in situ hybridization (FISH) or conventional karyotyping; high risk criteria based on commercially available gene expression profiling; OR

• Extramedullary disease, plasma cell leukemia or high lactate dehydrogenase (LDH)

• Participants must have histologically documented myelofibrosis (MF)

• Participants with Dynamic International Prognostic Scoring System (DIPSS) plus intermediate stage 2 or higher risk MF; OR

• Subset of intermediate stage 1 participants; defined by:

• Poor-risk molecular profile (triple negative: JAK2, CALR, MPL); OR

• Presence of any of the following mutations: ASXL1, SRSF2, EZH2, IDH1/2; OR

• Severe thrombocytopenia, severe anemia, high peripheral blood blasts percentage; OR

• Unfavorable cytogenetic abnormalities (rearrangements of chromosome 5 or 7 or >= 3 abnormalities

• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines

• DONOR: A related donor - fully matched

• DONOR: A related donor - haploidentical

• DONOR: An unrelated donor - fully matched

• DONOR: An unrelated donor -9/10 matched

Exclusion Criteria:

• Cardiac-left ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmias

• Pulmonary-forced expiratory volume at one second (FEV1) or diffusion capacity of lung for carbon dioxide (DLCO) < 40% or history of chronic use of supplemental oxygen. Temporary use of supplemental oxygen at the time of screening or registration is allowed if the investigator feels that the underlying cause of requiring oxygen is reversible by the time treatment begins.

• Renal-calculated or measured glomerular filtration rate (GFR) < 30 ml/min, dialysis-dependent, or history of renal transplant

• Hepatic-bilirubin > 2 X upper limit of normal (ULN)

• Alanine aminotransferase (ALT) > 2.5 X ULN or cirrhosis

• Participants with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy

• Pregnant women, nursing mothers or women of child-bearing potential who are unwilling to use medically accepted methods of contraception

• Male and female subjects not willing to agree to medically accepted methods of contraception

Related Conditions & MeSH terms

• Anemia
• ASXL1 Gene Mutation
• EZH2 Gene Mutation
• IDH1 Gene Mutation
• IDH2 Gene Mutation
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Myeloma
• Primary Myelofibrosis
• Recurrent Plasma Cell Myeloma
• Secondary Myelofibrosis
• Thrombocytopenia

Intervention

Drug:
• Busulfan
Given IV
• Cyclophosphamide
Given IV
• Fludarabine
Given IV

Procedure:
• Hematopoietic Cell Transplantation
Undergo HSCT

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute/University of Utah	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-relapse Mortality (NRM) at Day 100	NRM is defined as death due to GVHD, infections, sepsis, organ (lung, liver, kidney) toxicity. Death from underlying disease (i.e. progression or relapse) is not considered NRM.	Up to day 100
Secondary	Non-relapse Mortality (NRM) at Day 365	NRM is defined as death due to GVHD, infections, sepsis, organ (lung, liver, kidney) toxicity. Death from underlying disease (i.e. progression or relapse) is not considered NRM.	Up to day 365
Secondary	Incidence of Acute Graft Versus Host Disease (GVHD)	Cases of acute graft versus host disease (GVHD) will be diagnosed by the treating physician and will be reported as a count of participants with acute GVHD.	Up to day 365
Secondary	Incidence of Chronic GVHD	Chronic GVHD will be assessed based on criteria established by the National Institutes of Health Consensus Development Project in 2005, and recently updated in 2014. This will be reported as a count of participants diagnosed with chronic GVHD	Up to day 365
Secondary	Overall Survival at One Year	Overall survival is defined as the number of participants remaining alive up to one year following stem cell transplant.	Up to 1 year
Secondary	Disease Free Survival at One Year	Disease free survival is defined as an absence of disease relapse or progression up to one year following stem cell transplant.	Up to 1 year
Secondary	Number of Participants With Different Clinical Responses	Clinical Responses were determined by disease-specific criteria taking into account multiple clinical and molecular markers. Multiple Myeloma (MM) response was determined using International Myeloma Working Group (IMWG) consensus criteria for response. Participants with MM had either Stringent Complete Response (sCR) or Very Good Partial Response (VGPR). Myelofibrosis (MF) response was determined using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus criteria. Participants with MF had either Complete Response (CR) or Stable Disease (SD) (also referred to in the protocol as no response).	Up to 1 year
Secondary	Number of Participants With Minimal Residual Disease (MRD) Response	After bone marrow transplant, bone marrow was collected every 3-6 months (as clinically indicated per treating investigator) for up to one year after bone marrow transplant. Bone marrow was evaluated by a clinical pathologist for any evidence of multiple myeloma (MM) or myelofibrosis (MF). Evidence of MM or MF in the bone marrow is referred to as minimal residual disease (MRD). A participant with evidence of MRD is MRD-positive. A participant with no evidence of MRD is MRD-negative, which is considered an MRD response. This outcome reports the number participants with MRD responses any time between bone marrow transplant up to one year of follow-up.	Up to 1 year